Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

T Cell Dysfunction, Cancer and Infection (A3)


Organizer(s) Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok
January 16—20, 2018
Beaver Run Resort • Breckenridge, Colorado USA
Discounted Abstract Deadline: Sep 21, 2017
Abstract Deadline: Oct 19, 2017
Scholarship Deadline: Sep 21, 2017
Discounted Registration Deadline: Nov 20, 2017

Sponsored by Amgen Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology and TESARO, Inc.

Summary of Meeting:
T cell exhaustion is an acquired state of T cell dysfunction, associated with reduced T cell function, sustained expression of inhibitory receptors and a transcriptional state that is distinct from memory and effector T cells. T cell exhaustion is now recognized as a defining feature not only of chronic infections such as HIV, malaria and tuberculosis, but also of cancer. As a result, the search for effective approaches to reverse T cell exhaustion is the focus of immense therapeutic development. However, the similarities and differences between T cell dysfunction arising in chronic infection and tumors are not fully understood. Moreover, opportunities to identify new therapeutic approaches to reverse dysfunction based on parallels between the two disease states remain to be explored. This meeting will focus on the comparative biology and clinical therapeutics of T cell dysfunction in chronic viral infection and cancer. Drawing on leaders in fundamental T cell biology, computational science and clinical investigation, it will focus on common features and distinctive aspects of T cell dysfunction in cancer and chronic infection. The meeting will have broad relevance for T cell biology, tumor immunity, infectious disease and therapeutic development.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Tuesday, January 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, January 20 with a closing plenary session and keynote address from 17:00 to 19:15, followed by a social hour and entertainment. We recommend return travel on Sunday, January 21 in order to fully experience the meeting.

TUESDAY, JANUARY 16

16:00—20:00
Arrival and Registration

Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Foyer

WEDNESDAY, JANUARY 17

07:00—08:00
Breakfast

Breckenridge Ballroom
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Daniel C. Douek, NIAID, National Institutes of Health, USA

* W. Nicholas Haining, Dana-Farber Cancer Institute, USA

Rafi Ahmed, Emory University School of Medicine, USA
A New Look at T Cell Exhaustion

09:00—11:30
Adoptive T Cell Therapy for Cancer
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Susan M. Kaech, The Salk Institute, USA

Crystal L. Mackall, Stanford University, USA
Use of Adoptive T Cell Transfer in Pediatric Patients

Coffee Break

Cassian Yee, University of Texas MD Anderson Cancer Center, USA
Endogenous T Cell Therapy: Finding Dory

Michael C. Jensen, University of Washington School of Medicine/Fred Hutchinson Cancer Research Center, USA
Overcoming Barriers to Achieving Curative Outcomes Following CD19CAR T Cell Therapy For Recurrent/Refractory Pediatric ALL

Cyrille J. Cohen, Bar-Ilan University, Israel
Short Talk: Improved Targeting of Multiple Tumors and Viral-Infected Cells using T-Cells Engineered to Express NCR-Based Chimeric Receptors

Lexus Johnson, University of Pennsylvania, USA
Short Talk: Intratumoral Immune Activation Informs Rational CAR T Cell Design

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Foyer
17:00—19:00
T Cells and their Microenvironment
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* W. Nicholas Haining, Dana-Farber Cancer Institute, USA

Daniel C. Douek, NIAID, National Institutes of Health, USA
Influence of the Systemic Microbiome on Inflammation During HIV Infection

David G. Brooks, Princess Margaret Cancer Center, Canada
Type I Interferons and Inflammation in T Cell Immunity

Susan M. Kaech, The Salk Institute, USA
Anti-Tumor T Cells: You Are What You Eat

Rafick-Pierre Sekaly, Case Western Reserve University, USA
Short Talk: PD-1 and IL-1 Control Two Independent Mechanisms of Immune Dysfunction and Response to Treatment in Cancer and HIV

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 1

Breckenridge Ballroom

THURSDAY, JANUARY 18

07:00—08:00
Breakfast

Breckenridge Ballroom
08:00—11:15
Basic Biology of T Cell Exhaustion
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* E. John Wherry, University of Pennsylvania, USA

W. Nicholas Haining, Dana-Farber Cancer Institute, USA
The Epigenetic Landscape of T Cell Exhaustion

Ananda W. Goldrath, University of California, San Diego, USA
Transcriptional Regulation of CD8 T Cell Immunity

Coffee Break

Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Tumor-Specific T Cell Dysfunction

Dietmar Zehn, Technical University of Munich, Germany
Subsets and T Cell Differentiation in Chronic LCMV Infection

Curtis H. Cai, University of New South Wales, Australia
Short Talk: Elucidating the Factors Associated with Dysfunctional T-cell Responses in HCV Infection using scRNA-seq and Functional Analyses

Jennifer M. Dan, University of California, San Diego, USA
Short Talk: Recurrent Group A Streptococcus Tonsillitis Is a Genetic Immunosusceptibility Disease with Aberrant Follicular Helper CD4+ T Cells

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Adoptive T Cell Transfer for Infection
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Robert Thimme, University Medical Center Freiburg, Germany

Philip D. Greenberg, University of Washington, USA
Novel Approaches to Isolating Receptors and Engineering Cells to Target Tumor Antigens

James L. Riley, University of Pennsylvania, USA
Engineering T Cells to Functionally Cure HIV-1 Infection

Catherine M. Bollard, Children’s National Health System, USA
Virus-Specific T Cells Post HSCT- Broadening Applicability

Sanjivan Sanjivan Gautam, NCI, National Institutes of Health, USA
Short Talk: The Transcription Factor Myb Enhances CD8+ T Cell Memory and Anti-Tumor Function by Inducing Tcf7 and Restraining Zeb2 Transcription

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 2

Breckenridge Ballroom

FRIDAY, JANUARY 19

07:00—08:00
Breakfast

Breckenridge Ballroom
08:00—11:15
Basic Biology of Inhibitory Receptors
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Rafick-Pierre Sekaly, Case Western Reserve University, USA

Arlene H. Sharpe, Harvard Medical School, USA
The Role of the PD-1 Pathway in Regulating Immunity

Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
LAG3: Function, Mode of Action and its Impact on Cancer Immunotherapy

Coffee Break

Sadna Budhu, Memorial Sloan Kettering Cancer Center, USA
Blockade of Surface-Bound TGF-β on Regulatory T Cells Abrogates Suppression of Effector T Cell Function in the Tumor Microenvironment

Ira Mellman, Genentech, Inc., USA
PD-L1 Blockade and Targeted Therapy

Frédéric Duval, University of Montreal, Canada
Short Talk: Notch Signaling Dampens Cd8 T Cell Exhaustion During Chronic Infection

Hazem E. Ghoneim, St Jude Children's Research Hospital, USA
Short Talk: Inhibiting Exhaustion-Associated Epigenetic Programs Enhances PD-1 Blockade-Mediated T Cell Rejuvenation

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Foyer
17:00—19:00
Checkpoint Blockade
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Daniel C. Douek, NIAID, National Institutes of Health, USA

Roberta Zappasodi, Memorial Sloan-Kettering Cancer Center, USA
Non-conventional Immunosuppressive TFH-like CD4+ T Cells Promote Resistance to Immune Checkpoint Blockade Therapy

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Virus-Associated Cancers: Intersection of Antitumor Immunity and Infectious Immunity

E. John Wherry, University of Pennsylvania, USA
T Cell Exhaustion and Immunotherapy

Rebecca Dookie, University of Manchester, UK
Short Talk: Investigating the Role of Checkpoint Inhibitors in Malaria-Induced T Cell Exhaustion

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 3

Breckenridge Ballroom

SATURDAY, JANUARY 20

07:00—08:00
Breakfast

Breckenridge Ballroom
08:00—11:00
Targets for T Cells
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Robert A. Seder, NIAID, National Institutes of Health, USA

Robert Thimme, University Medical Center Freiburg, Germany
Impact of Antigen Recognition on T Cell Diversification in Chronic Viral Hepatitis

Pramod K. Srivastava, University of Connecticut School of Medicine, USA
Broadening the View of Mutational Antigens for Cancer Immunotherapy

Coffee Break

Lélia Delamarre, Genentech, Inc., USA
Determinants of Cancer Neoantigen Immunogenicity

Brendan Bulik-Sullivan, Gritstone Oncology, USA
Short Talk: Antigen Identification for Cancer Immunotherapy by Deep Learning on Tumor HLA Peptides

Thomas Duhen, Agonox, USA
Short Talk: Co-Expression of CD39 and CD103 Identifies Tumor-Reactive CD8 TIL in Human Solid Tumors

11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Foyer
17:00—18:15
Vaccines to Revive T Cell Responses
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA

Robert A. Seder, NIAID, National Institutes of Health, USA
Adjuvants for T Cell Vaccines

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Boosting T Cells by Getting Vaccines Where They Need to Go

18:15—19:00
Closing Keynote Address
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Daniel C. Douek, NIAID, National Institutes of Health, USA

Carl H. June, University of Pennsylvania, USA
Enhancing Engineered T Cell Therapy for Cancer

19:00—19:15
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Breckenridge Ballroom

SUNDAY, JANUARY 21

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Amgen Inc. Incyte Corporation
Juno Therapeutics Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc. Surface Oncology
TESARO, Inc.
 

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA224785-01

Funding for this conference was made possible (in part) by 1 R13 CA224785-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

Oncotarget

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genentech, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676